282 related articles for article (PubMed ID: 22781599)
1. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599
[TBL] [Abstract][Full Text] [Related]
2. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
Schneppenheim R; Michiels JJ; Obser T; Oyen F; Pieconka A; Schneppenheim S; Will K; Zieger B; Budde U
Blood; 2010 Jun; 115(23):4894-901. PubMed ID: 20351307
[TBL] [Abstract][Full Text] [Related]
3. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.
Casonato A; Pontara E; Battiston M; Morpurgo M; Cattini MG; Casarin E; Saga G; Daidone V; De Marco L
Thromb Haemost; 2013 Jun; 109(6):999-1006. PubMed ID: 23446343
[TBL] [Abstract][Full Text] [Related]
4. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13.
Ma Z; Su J; Zhang J; Ling J; Yin J; Bai X; Ruan C
Thromb Res; 2015 Nov; 136(5):987-95. PubMed ID: 26345337
[TBL] [Abstract][Full Text] [Related]
5. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.
Jacobi PM; Gill JC; Flood VH; Jakab DA; Friedman KD; Haberichter SL
Blood; 2012 May; 119(19):4543-53. PubMed ID: 22431572
[TBL] [Abstract][Full Text] [Related]
6. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.
Hassenpflug WA; Budde U; Obser T; Angerhaus D; Drewke E; Schneppenheim S; Schneppenheim R
Blood; 2006 Mar; 107(6):2339-45. PubMed ID: 16322474
[TBL] [Abstract][Full Text] [Related]
7. The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity.
Daidone V; Saga G; Barbon G; Pontara E; Cattini MG; Morpurgo M; Zanotti G; Casonato A
Br J Haematol; 2015 Aug; 170(4):564-73. PubMed ID: 25904363
[TBL] [Abstract][Full Text] [Related]
8. Modeling ADAMTS13-von Willebrand factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand disease.
Pozzi N; Lancellotti S; De Cristofaro R; De Filippis V
Biophys Chem; 2012 Jan; 160(1):1-11. PubMed ID: 21937160
[TBL] [Abstract][Full Text] [Related]
9. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
O'Brien LA; Sutherland JJ; Hegadorn C; Benford K; Racz H; Rapson D; Hough C; Lillicrap D
J Thromb Haemost; 2004 Jul; 2(7):1135-42. PubMed ID: 15219197
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.
Obser T; Ledford-Kraemer M; Oyen F; Brehm MA; Denis CV; Marschalek R; Montgomery RR; Sadler JE; Schneppenheim S; Budde U; Schneppenheim R
J Thromb Haemost; 2016 Sep; 14(9):1725-35. PubMed ID: 27344059
[TBL] [Abstract][Full Text] [Related]
11. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.
Rayes J; Hommais A; Legendre P; Tout H; Veyradier A; Obert B; Ribba AS; Girma JP
J Thromb Haemost; 2007 Feb; 5(2):321-8. PubMed ID: 17087728
[TBL] [Abstract][Full Text] [Related]
12. L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
Kashiwagi T; Matsushita T; Ito Y; Hirashima K; Sanda N; Fujimori Y; Yamada T; Okumura K; Takagi A; Murate T; Katsumi A; Takamatsu J; Yamamoto K; Naoe T; Kojima T
Haemophilia; 2008 May; 14(3):556-63. PubMed ID: 18397285
[TBL] [Abstract][Full Text] [Related]
13. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.
Lynch CJ; Cawte AD; Millar CM; Rueda D; Lane DA
PLoS One; 2017; 12(11):e0188405. PubMed ID: 29186156
[TBL] [Abstract][Full Text] [Related]
14. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
15. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
Pruss CM; Notley CR; Hegadorn CA; O'Brien LA; Lillicrap D
Br J Haematol; 2008 Nov; 143(4):552-8. PubMed ID: 18986390
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.
Tsai HM; Sussman II; Ginsburg D; Lankhof H; Sixma JJ; Nagel RL
Blood; 1997 Mar; 89(6):1954-62. PubMed ID: 9058716
[TBL] [Abstract][Full Text] [Related]
18. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
Chegeni R; Vickars L; Favaloro EJ; Lillicrap D; Othman M
Thromb Res; 2011 Feb; 127(2):161-6. PubMed ID: 21094983
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.
Dong J; Zhao X; Shi S; Ma Z; Liu M; Wu Q; Ruan C; Dong N
PLoS One; 2012; 7(3):e33263. PubMed ID: 22479377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
